Faruqi & Faruqi, LLP is investigating claims against Aardvark Therapeutics for allegedly misleading investors in its February 2025 IPO and subsequent securities offerings. The lawsuit alleges the company made false statements about the safety and prospects of its drug ARD-101, which led to significant stock price drops after clinical trial pauses and an FDA hold. Investors who bought shares during the period can seek lead plaintiff status by October 13, 2026, or participate as class members. The firm encourages affected investors and whistleblowers to contact them to discuss legal options and potential recovery.
Xiaomi Corp reported better-than-expected earnings per share of $0.05 and revenue of $16.04 billion, surpassing analyst forecasts. However, the company faces significant margin pressure from rising component costs and weaker consumer demand, causing ...
Mercury Systems, a tech company in aerospace and defense, is expected to report Q2 earnings with EPS of $0.38, a 19.2% drop year-over-year, and revenue of $266.10 million, down 3%. Despite the decline, the company maintains a low debt-to-equity ratio...
An analyst from Scotiabank raised the price target for Public Storage (NYSE: PSA) to $346, suggesting a potential 5.75% upside from the current price of $327.18. Institutional investors like Capital Financial Group and Harvest Fund Management have in...
Corporacion America Airports reported Q2 2026 revenue of $534 million, surpassing analyst estimates of $497.52 million, showing strong sales performance. However, earnings per share (EPS) came in at $0.32, below the expected $0.51, indicating lower p...
Analysts have raised their price targets for Cheniere Energy, signaling confidence in the company's future growth. Argus increased its target to $330, suggesting a 20.33% upside from the current price of around $274. TD Cowen also raised its target t...
